Up­dat­ed: A week af­ter GSK pulls one Ze­ju­la in­di­ca­tion, FDA sets ODAC meet­ing to re­view re­vis­ing la­bel fur­ther

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee will meet on Nov. 22 to dis­cuss whether to pull an in­di­ca­tion for GSK’s ovar­i­an can­cer drug Ze­ju­la, con­sid­er­ing the fi­nal over­all sur­vival da­ta from the piv­otal tri­al on which the ap­proval was based.

ODAC will hear an up­date (the FDA press re­lease at the time nev­er men­tions OS) on Ze­ju­la’s ap­proval for the main­te­nance treat­ment of adult pa­tients with re­cur­rent ep­ithe­lial ovar­i­an, fal­lop­i­an tube, or pri­ma­ry peri­toneal can­cer who are in a com­plete or par­tial re­sponse to plat­inum-based chemother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER